Andrew Hattersley

Has grant

Professor of Molecular Medicine

University of Exeter

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Andrew Hattersley is a Professor of Molecular Medicine at the University of Exeter, UK. His research focuses on the genetic and clinical aspects of diabetes, including the prevalence of G6PD deficiency and its impact on health inequalities. He has notably contributed to studies on monogenic diabetes, drug effectiveness in type 2 diabetes treatment, and the genetic factors influencing diabetes risk. His recent articles highlight the importance of understanding ethnic differences in diabetes manifestation and the implications of in utero treatment on neonatal diabetes outcomes.

Recent Grants

Grant: Open

NIHR Exeter BRC

Open Date: 2022-12-01

Close Date: 2027-11-01

Grant: Open

Human-specific gene regulation in pancreatic beta-cell development

Open Date: 2022-04-01

Close Date: 2027-03-01

Grant: Close

Developing a decision support tool to enable precision treatment of type 2 diabetes

Open Date: 2021-10-01

Close Date: 2024-09-01

Grant: Close

EPSRC Hub for Quantitative Modelling in Healthcare

Open Date: 2020-08-31

Close Date: 2024-08-30

Grant: Close

Assessing the pathogenicity, penetrance and expressivity of monogenic disease variants using large-scale population-based cohorts

Open Date: 2020-08-31

Close Date: 2023-02-28

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrew Hattersley

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Improved Neurodevelopment Following In Utero Sulfonylurea Exposure in a Patient With KCNJ11 Permanent Neonatal Diabetes: Future Implications for Targeted Treatment During Pregnancy

Evaluating prediction of short‐term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population‐based study

Undiagnosed G6PD Deficiency in Black and Asian Individuals Is Prevalent and Contributes to Health Inequalities in Type 2 Diabetes Diagnosis and Complications

Common genetic variants modify disease risk and clinical presentation in monogenic diabetes

Rare Variants in NEUROD1 and PDX1 Are Low-Penetrance Causes of MODY, Whereas Those in APPL1 and WFS1 Are Not Associated With MODY

Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach

Comment on Garvey et al. Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial. Diabetes Care 2024;47:562–570

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Glibenclamide in a Young Adult With KCNJ11 Permanent Neonatal Diabetes

Widening the phenotypic spectrum caused by pathogenic PDX1 variants in individuals with neonatal diabetes

Ethnic differences in the manifestation of early-onset type 2 diabetes

Collaborators (7)

Sarah Flanagan

Susan Martin

Ewan Pearson

Jack Bowden

Pamela Bowman

Angus Jones

John Dennis

Make your next move.